About US
Contact us
-
Gilead caps 2012 roll by bagging cancer drugmakerGilead Sciences ($GILD) has seen its stock price grow more than 80% this year on a number of positive developments. Already a leader in medications for HIV, it got a new combo med approved a few mont2012/12/13
-
AOP Orphan Pharmaceuticals Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylate2012/12/13
-
India kills Merck patent in ongoing campaignIndia has done it again, revoking another patent from a Big Pharma player on the grounds that it shows no innovation. This time it nailed a Merck & Co. ($MRK) asthma drug, the Business Standard r2012/12/12
-
Levin lays out 4-year plan to turn Teva into a brandTeva Pharmaceuticals ($TEVA) has money in the bank, drugs in the pipeline and big plans for the future. Given those assets and four more years, CEO Jeremy Levin told investors on Tuesday they will ha2012/12/12
-
Pharmaceutical regulatory affairs teams continue to increase budgetsPharmaceutical companies have continued to boost the budgets allocated to their regulatory affairs teams, despite making overall spending cuts, a study suggests. Cutting Edge Information's latest stu2012/12/11
-
Merck wins back $500K in retaliation lawsuitThe courts giveth and the courts taketh away, and how you view those actions depends on which side of a lawsuit you sit on. In a recent ruling by a federal appeals court, Merck & Co. ($MRK) was ha2012/12/11
-
Endo revises pain drug recall from 1 to 101 lotsIn September, the generics subsidiary of Endo Health Solutions ($ENDP) voluntarily recalled one lot of two pain drugs that it called "super potent" because both exceeded their prescribed weights. Now2012/12/10
-
NICE snubs Pfizer's Inlyta kidney cancer drugPfizer ($PFE) has run into the U.K. watchdog wall of resistance to targeted cancer drugs with its renal cancer treatment Inlyta. The drugmaker was seeking approval for use in patients with advance2012/12/10
-
Another pharma free speech case hits U.S. appeals courtWhile we're still digesting the news that one U.S. appeals court figures off-label discussions are protected by the First Amendment, another panel is considering a similar argument. The Ninth Circuit2012/12/7
-
U.S. patient sues Ranbaxy over generic Lipitor recallLast month, Ranbaxy Laboratories recalled its version of the cholesterol-fighting pill Lipitor. By last week, the company had stopped making the drug, at least until it can iron out the manufacturing2012/12/7